S'abonner

Zika virus RNA and IgM persistence in blood compartments and body fluids: a prospective observational study - 26/11/20

Doi : 10.1016/S1473-3099(19)30708-X 
Mars Stone, PhD a, b, , Sonia Bakkour, PhD a, b, Marion C Lanteri, PhD a, b, c, Donald Brambilla, PhD d, Graham Simmons, ProfPhD a, b, Roberta Bruhn, PhD a, b, Zhanna Kaidarova, PhD a, Tzong-Hae Lee, MD a, Jose Orlando Alsina, MS e, Phillip C Williamson, PhD f, Susan A Galel, MD g, Lisa L Pate, MD g, Jeffrey M Linnen, PhD h, Steve Kleinman, ProfMD i, Michael P Busch, ProfMD a, b
for the

NHLBI Recipient Epidemiology Donor Evaluation Study REDS-III Program

a Vitalant Research Institute, San Francisco, CA, USA 
b Department of Laboratory Medicine, University of California, San Francisco, CA, USA 
c Cerus Corporation, Concord, CA, USA 
d RTI International, Rockville, MD, USA 
e Banco de Sangre de Servicios Mutuos, Guaynabo, PR, USA 
f Creative Testing Solutions, Tempe, AZ, USA 
g Roche Molecular Systems, Pleasanton, CA, USA 
h Grifols Diagnostic Solutions, San Diego, CA, USA 
i Department of Pathology and Laboratory Medicine, University of British Columbia, Victoria, BC, Canada 

* Correspondence to: Dr Mars Stone, Vitalant Research Institute, San Francisco, CA 94118, USA Vitalant Research Institute San Francisco CA 94118 USA

Summary

Background

Characterisation of the dynamics of Zika virus persistence following acute infection is needed to inform blood donor and diagnostic testing policies and understand the natural history of Zika virus infection. We aimed to characterise the natural history, persistence, and clinical outcomes of Zika virus infection through a prospective study in initially asymptomatic Zika virus RNA-positive blood donors.

Methods

Zika virus-infected blood donors identified through Zika virus nucleic acid amplification test (NAAT) screening at three blood collection organisations in the USA were enrolled into a 1-year follow-up study, with blood and body fluid samples and detailed symptom data collected at up to seven visits. All samples were tested for Zika virus RNA by real-time PCR (rtPCR); follow-up plasma, whole blood, and urine were also tested by replicate NAAT. Plasma was tested for flavivirus-specific IgM and IgG by ELISA. Zika virus RNA persistence for each assay or sample type and plasma antibody persistence from estimated date of plasma NAAT-detectable infection were calculated from follow-up data using survival statistical methods.

Findings

Between July 6, 2016 and March 7, 2017, we enrolled 53 participants. From the estimated date of plasma NAAT-detectable infection, Zika virus RNA was detectable in plasma for 9·9 days (95% CI 8·1–12·0), in red blood cells for 95·4 days (62·8–129·1), and in whole blood for 73·5 days (39·8–107·5). Replicate NAATs (one or more of eight replicates positive) extended detection of Zika virus RNA in plasma to 34·8 days (19·9–56·2) and in whole blood (at least one of two tests positive) to 104·8 days (76·7–129·9). Urine was rtPCR reactive up to 14·5 days (10·5–20·3) and saliva up to 26·4 days (19·7–38·7). Zika virus IgM persisted for 237·7 days (128·7–459·5) from estimated time since plasma NAAT-detectable infection. Zika virus RNA fell below detectable limits more rapidly in the saliva of participants with pre-existing dengue virus IgG than in those without. Of 25 donors identified pre-seroconversion with symptom data at the first or second study visit, 16 (64%) developed multiple Zika virus-related symptoms after asymptomatic index donations, compared with nine (36%) of 25 donors detected after seroconversion.

Interpretation

Determination of viral marker persistence is enhanced by follow-up of blood donors who are pre-symptomatic or asymptomatic, Zika virus RNA-positive, and antibody negative. Zika virus RNA persists in red blood cells for several months following clearance from plasma and body fluids, and replicate, highly sensitive NAATs extend RNA detection in all compartments. Whole blood testing can extend detection of acute infection for diagnostics and monitoring of pregnant women, sexual partners, and travellers.

Funding

National Heart, Lung, and Blood Institute, Biomedical Advanced Research and Development Authority.

Le texte complet de cet article est disponible en PDF.

Plan


© 2020  Elsevier Ltd. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 20 - N° 12

P. 1446-1456 - décembre 2020 Retour au numéro
Article précédent Article précédent
  • Evolving viral and serological stages of Zika virus RNA-positive blood donors and estimation of incidence of infection during the 2016 Puerto Rican Zika epidemic: an observational cohort study
  • Phillip C Williamson, Brad J Biggerstaff, Graham Simmons, Mars Stone, Val Winkelman, Gerardo Latoni, Jose Alsina, Sonia Bakkour, Christina Newman, Lisa L Pate, Susan A Galel, Steven Kleinman, Michael P Busch
| Article suivant Article suivant
  • Interferon-? release assays or tuberculin skin test for detection and management of latent tuberculosis infection: a systematic review and meta-analysis
  • Guozhong Zhou, Qingyi Luo, Shiqi Luo, Zhaowei Teng, Zhenhua Ji, Jiaru Yang, Feng Wang, Shiyuan Wen, Zhe Ding, Lianbao Li, Taigui Chen, Manzama-Esso Abi, Miaomiao Jian, Lisha Luo, Aihua Liu, Fukai Bao

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.